tion by LC-MS/MS may be useful for monitoring therapeutic efficacy of mannose. The discovery of these small N-glycans also indicates the presence of an alternative pathway in N-glycosylation not recognized previously, but its biological significance remains to be studied.
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Congenital disorders of glycosylation (CDGs) 11 are a group of diseases with highly variable phenotypes and inconsistent clinical features. Since the first description of a CDG in 1980, approximately 100 disorders have been identified (1 ) . Most are defects in protein glycosylation, although an increasing number are defects of glycolipid or proteoglycan biosynthesis. Protein glycosylation is the process of adding and remodeling glycans to proteins on either the amide group of asparagine residue (N-glycan) or the hydroxyl group of a serine or threonine residue (O-glycan). Both the structure and function of N-and O-glycans in humans are highly diverse. Excluding O-GlcNAcylated proteins, Ն85% of human proteins with a secretory signal sequence are N-or O-glycosylated (2 ) .
Transferrin is a serum glycoprotein that has 2 N-glycosylation sites, and each glycan contains Յ2 terminal, negatively charged sialic acids. The glycoforms of transferrin are widely used as a biomarker of N-glycosylation defects. Alterations in the number or structure of transferrin glycoforms can be detected by isoelectric focusing, HPLC, capillary electrophoresis, or electrospray ionization (ESI)-LC-MS (3 ) . Although analysis of carbohydrate-deficient transferrin reliably identifies the majority of the N-linked hypoglycosylation disorders, it does not distinguish CDG subtypes, which requires gene sequencing and functional confirmation. Here we show that application of MALDI-TOF-MS analysis to total serum N-glycans identifies small N-glycans devoid of mannose. Measuring these N-glycans in plasma and cultured fibroblast lysates distinguishes among unaffected controls and patients with ALG1-CDG, PMM2-CDG, or MPI-CDG, which are the CDG types caused by ALG1 [ALG1 (asparagine-linked glycosylation protein 1), chitobiosyldiphosphodolichol ␤-mannosyltransferase],
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PMM2 (phosphomannomutase 2), and MPI (mannose phosphate isomerase), respectively. Unlike transferrin, a glycoprotein that is predominantly synthesized in the liver, total N-glycans can be measured from samples other than blood, such as urine and fibroblast lysates. This makes N-glycan profiles ideal for biochemical diagnosis, in vitro studies of CDG pathogenesis, and monitoring effectiveness of treatment. Additionally, such analyses can lead to the identification of novel N-glycans with diagnostic and therapeutic significance.
Materials and Methods
Iodomethane (CH 3 I), DMSO, 2,5-dihydroxybenzoic acid (DHB), sodium hydroxide, trifluoroacetic acid, sodium borohydrate, and sodium acetate were obtained from Sigma-Aldrich; PNGase F, including denaturing buffer, digestion buffer, and NP-40, from New England Biolabs; Extra-Clean SPE Carbograph columns from Grace Davison Discovery Sciences; Sep-Pak Vac 3cc C18 cartridges from Waters; p-lacto-N-hexaose from V-Laboratories; and methanol, chloroform, and acetonitrile from Fisher Scientific.
PREPARATION AND PERMETHYLATION OF PLASMA OR CELLULAR PROTEIN LYSATES
As previously described (4 ), we prepared N-glycan samples by PNGase F digestion at 37°C for 16 h after the total plasma or serum proteins were denatured by incubation at 100°C for 10 min. We used 20 L serum or plasma for N-glycan preparation. For cellular N-linked glycan preparation, 100 g total cellular protein from total cell lysate was denatured and precipitated with propanol (1:2 vol/vol, such as 100 L cell lysate/200 L propanol) before PNGaseF digestion. The released N-linked glycans were purified through a Sep-Pak C18 column, to which they did not bind, followed by binding and release from a carbograph column with acetonitrile as the eluant. All the purified glycans were lyophilized overnight.
For permethylation, we crushed 4 NaOH pellets (approximately 375 mg) in 10 mL anhydrous DMSO and added 0.5 mL of this slurry and 0.2 mL CH 3 I to the dried glycans. The mixture was shaken vigorously for 1 h followed by 5 sequential chloroform/water (600 L/200 L) extractions. The chloroform fractions were pooled and dried for 30 min under nitrogen. The permethylated N-glycans were resuspended in 50 L of 50% methanol and further purified through a C18 Stage Tip (Thermo Scientific), to which they did bind, and were eluted with acetonitrile as previously described (4 ).
ANALYSIS OF N-GLYCAN PROFILES BY MALDI-TOF-MS
Each permethylated N-glycan sample (0.5 L) was spotted onto the MALDI plate, and 0.5 L DHB (11 g/L in 50% methanol with 1 mmol/L sodium acetate) was added as a matrix solution. Each spot was then air-dried for 10 min. The data were generated with a MALDI-TOF-MS 4800 plus (Applied Biosystems) in positive reflector mode with the laser power set at 4880 and the digitizer set at 0.79. Each sample was run 3 times.
We selected 20 specific N-glycans for semiquantitative analysis and normalization of intensities to the sum of all the peaks. The ratios of the most abundant glycan (m/z 2792) and the internal standard (m/z 1357 or 926) were recorded to monitor the yield of glycan. We used 4000 series Explorer software (Applied Biosystems) to collect data and integrate peak intensities. All the glycans were identified as singly charged [MϩNa] ϩ .
QUANTIFICATION OF N-LINKED GLYCANS BY LC-MS/MS
We analyzed permethylated glycans on an ABSIEX QTRAP 5500 mass spectrometer equipped with a Shimadzu Prominence UFLC system that consisted of 2 LC-20AD solvent delivery units, a DGU-20A 3 degassing unit, a SIL-20AC HT autosampler, a CTO-20A column oven, and a CMB-20A system controller.
Permethylated N-glycans were separated on a Thermo Scientific Hypersil™ GOLD HPLC Column, 3-m particle size, 30 ϫ 2.1 mm, at a flow rate of 0.25 mL/min. The column was maintained at 35°C in a column oven. The gradient was started with 55% mobile phase A (20 mL acetonitrile and 1 mL formic acid in 979 mL ultrapure water) and 45% mobile phase B (979 mL acetonitrile, 1 mL formic acid, and 20 mL ultrapure water); mobile phase B was increased to 60% at 5 min and to 100% at 5.5 min and reverted to 45% at 13 min to equilibrate for 3 min.
The mass spectrometer was operated in positive ESI mode. Nitrogen from an Infinity 1031 Nitrogen generator (PEAK) was used as the curtain gas (25 ), ion source gas 1 (45 ) and gas 2 (55 ), and collision gas (Medium). The ion spray voltage of the source was 5500, and the temperature was set at 600°C. Multiple reaction monitoring (MRM) for each targeted glycan was optimized with infusion of permethylated N-glycans in 80% acetonitrile containing 0.1% formic acid. The MRM transition used for the sialylated tetrasaccharide was 1102/825, and 1149/851 for the pentasaccharide Man 3 GlcNAc 2 . The internal standard used for quantification of N-glycans by LC-MS/MS was raffinose with a MRM transition of 681/463. The quantification of N-tetrasaccharide (see below) and disialo-glycan (VLaboratories) was achieved by LC-MS/MS with external standards.
SYNTHESIS, PURIFICATION, AND QUANTIFICATION OF N-TETRASACCHARIDE
Chitobiose, a disaccharide GlcNAc␤1,4GlcNAc (SigmaAldrich), was galactosylated with a ␤1,4-galactosyltransferase kit (Sigma) following the manufacturer's instructions. Briefly, 379 mg Trizma hydrochloride buffer, pH 7.4, and 198 mg MnCl 2 were dissolved in 50 mL MilliQ water. To 1.0 mL of the reaction buffer, we added 10 mmol/L chitobiose, 7.3 mg UDP-galactose, 1 mg BSA, 1 L alkaline phosphatase (10 U/mL), and 50 mU ␤1,4-galactosyltransferase. The reaction mixture was incubated at 37°C overnight, and the product was purified on a Sep-Pak C18 column followed by a carbograph column as described above. The addition of sialic acid to Gal␤1,4GlcNAc␤1,4GlcNAc was achieved with ␣2,3-sialyltransferase (Sigma) or ␣2,6-sialyltransferase (Sigma). Enzymatic reactions were performed at 37°C overnight in Tris-HCl buffer (100 mmol/L, pH 8.0) containing 5 mmol/L CMP-sialic acid (CMP-Neu5Ac), 2 U ␣2,3-sialyltransferase, or 5 U ␣2,6-sialyltransferase. The product tetrasaccharides from the separate reactions with sialyltransferases (Neu5Ac␣2,3Gal␤1,4GlcNAc␤1,4GlcNAc and Neu5Ac␣2,6Gal␤1,4GlcNAc␤1,4GlcNAc) were purified on a Sep-Pak C18 column and then on a carbograph column. We determined the concentration of the resulting tetrasaccharide by 2-aminobenzamide (2-AB) labeling of the reducing end with a GlycoProfile™ 2-AB labeling kit (Sigma) or aniline after quantitative measurement by HPLC with a fluorescence detector or LC-MS/MS, respectively, as previously described (5, 6 ) . We used MRM transition 937/ 671 for the tetrasaccharide labeled with aniline. We used 2-AB labeling for measuring the concentration of synthesized standard and aniline labeling for optimal separation of 2,3-and 2,6-sialylated tetrasaccharide on LC-MS/MS.
Results
We identified a set of small N-glycans in the plasma of a patient with pathogenic mutations in ALG1, defined as those released by PNGase F, at m/z 559, 763, and 1124 ( Fig. 1 , B and C, and Supplemental Fig. 1B , which accompanies the online version of this article at http:// www.clinchem.org/content/vol62/issue1); these were absent in unaffected control plasma (Fig. 1A , online Supplemental Fig. 1A ). From the mass of each of these glycans and the fragmentation pattern of the tetrasaccharide (Fig. 1D) , we predicted them to be chitobiose (GlcNAc 2 ) (m/z 559), galactosylated chitobiose (Gal 1 GlcNAc 2 ) (m/z 763), and a sialylated tetrasaccharide (Sial 1 Gal 1 GlcNAc 2 ) (m/z 1124), respectively. Because these glycans were lacking in the purified free glycans (see online Supplemental Fig.  1C ) or the O-glycans released by ␤-elimination of total glycoproteins (data not shown) from the same plasma sample, we concluded that they were N-glycans specifically released by PNGase F digestion. We designated the tetrasaccharide as the N-tetrasaccharide.
We also detected small amounts of "non"-glycosylated transferrin monomer with the Ntetrasaccharide at observed mass 76 017 (predicted mass 76 016) and "mono"-glycosylated transferrin with an N-tetrasaccharide at observed mass 78 215 (predicted mass 78 222) (Fig. 1E ). These glycoforms of transferrin represented only 2%-5% of the signal of the major transferrin species in the ESI-MS profile of ALG1-CDG transferrin. However, ESI-MS analysis of transferrin was an indirect measurement through convolution of the multiple charge envelopes, and the majority of the convolution software used for ESI-MS was not designed for quantitative interpretation of peaks with low abundance compared to the major peaks.
Analysis of PNGase F-released material from purified transferrin of the ALG1-CDG patient sample also identified the N-tetrasaccharide (Fig. 1G) . The tetrasaccharide was not observed in unaffected controls (Fig. 1F) .
We hypothesized that the presence of this small N-tetrasaccharide was due to reduced mannosylation of lipid-linked chitobiose in the endoplasmic reticulum. For example, ALG1-deficient yeast accumulates dolichol-linked chitobiose (GlcNAc␤1,4GlcNAc-P-P-Dol). This intermediate can be transferred to nascent proteins, producing N-linked chitobiose (7 ) . Because the fragmentation pattern of the N-tetrasaccharide (Fig. 1D ) predicted it to have the composition Sial 1 Hexose 1 HexNAc 2 , we hypothesized that N-linked chitobiose-modified proteins reach the Golgi apparatus and act as acceptors for Golgi ␤1,4-galactosyltransferase, which adds galactose, and an ␣2,3-and/or ␣2,6-sialyltransferase, which adds a sialic acid. We compared the unknown N-tetrasaccharide to 2 synthetic tetrasaccharide standards, Neu5Ac␣2,3Gal␤1,4GlcNAc␤1, 4GlcNAc and Neu5Ac␣2,6Gal␤1,4GlcNAc␤1,4GlcNAc. The results showed that Neu5Ac␣2,6Gal␤1, 4GlcNAc␤1,4GlcNAc had the same retention time and mass fragmentation pattern as the unknown N-tetrasaccharide (Fig. 2, A and B) . Thus, we concluded that the N-tetrasaccharide had the sequence Neu5Ac␣2,6Gal␤1,4GlcNAc␤1,4GlcNAc.
Because a mannosylation deficiency also occurs in patients with PMM2-CDG or MPI-CDG owing to deficiency in GDP-mannose, we hypothesized that the novel N-tetrasaccharide also occurs in these 2 subtypes of CDG. To explore this possibility, we analyzed the N-glycan profiles from total plasma glycoproteins of a MPI-CDG, but not in patients with ALG1-CDG. The plasma N-glycan profiles for patients with PMM2-CDG or MPI-CDG were indistinguishable ( Fig. 1C and Fig.  3E ). Interestingly, analyzing N-glycan profiles of purified transferrin from a patient with PMM2-CDG detected the N-tetrasaccharide; however, increased Man 3 GlcNAc 2 or Man 4 GlcNAc 2 in PMM2-CDG plasma N-glycans was not detected in its transferrin N-glycan (Fig. 1H) , suggesting that Man 3 GlcNAc 2 and Man 4 GlcNAc 2 were more abundant in other plasma glycoproteins such as immunoglobulins.
We next developed a quantitative assay for the N-tetrasaccharide and for Man 3 GlcNAc 2 using LC-MS/MS (Fig. 2, D-F) . Measurement of the plasma N-tetrasaccharide and Man 3 GlcNAc 2 in 10 patients with putative or confirmed ALG1-CDG (mutations and putative mutations from patients with ALG1-CDG are shown in Table 1 ), 20 patients with PMM2-CDG, and 20 unaffected controls showed that the N-tetrasaccharide was undetectable in all the controls and present in all the patients with PMM2-CDG or ALG1-CDG (Fig. 2E) . The concentration of N-tetrasaccharide was the highest for patients with ALG1-CDG (Fig. 2E) . In addition, the relative ratio between the tetrasaccharide and Man 3 GlcNAc 2 was increased in patients with ALG1-CDG and within the reference range or low in patients with PMM2-CDG MPI-CDG (Fig. 2F and Fig. 3E ). These 2 measures successfully differentiated ALG1-CDG from PMM2-CDG, MPI-CDG, and unaffected controls and also differentiated PMM2-CDG and MPI-CDG from unaffected controls. The N-tetrasaccharide was undetectable in the plasma of patients with ALG12-CDG (CDG-Ig), DPAGT-CDG (CDG-Ij), ALG8-CDG (CDG-Ih), ALG6-CDG (CDG-Ic), Man1B1-CDG and DDOST-CDG (CDG-Ir), or mixed-type CDGs such as PGM1-CDG.
We also measured the relative quantity of the N-tetrasaccharide by LC-MS/MS after it was released from purified transferrin. The molar ratio between tetrasaccharide at m/z 1124 and transferrin monomers was 0.24 in ALG1-CDG and 0.02 in PMM2-CDG, vs a ratio of 2 between disialylated N-glycan at m/z 2792 and transferrin monomers in an unaffected control ( Table 2) . Quantification by LC-MS/MS showed that in purified ALG1-CDG transferrin, this tetrasaccharide was 13.8% of the major biantennary glycans, in contrast to 2% for PMM2-CDG transferrin. In comparison, the MALDI-TOF profile of N-glycans released from the same ALG1-CDG and PMM2-CDG samples showed that the tetrasaccharide comprised 34% and 5% of the biantennary glycans (Fig. 1, B and C) .
MALDI-TOF also identified the N-tetrasaccharide m/z 1124 in the N-glycan profiles of lysates from cultured fibroblasts of 5 patients with ALG1-CDG and 5 patients with PMM2-CDG, but not control fibroblasts (Fig. 3, A-C) . Because fibroblasts do not produce transferrin, the N-tetrasaccharide detected must be present in other cellular glycoproteins. Identification of the N-tetrasaccharide lacking mannose at m/z 1124 in patients with ALG1-CDG, PMM2-CDG, and MPI-CDG suggested that this small N-glycan reflected a deficiency in mannosylation. To test this, we added 500 mol/L mannose to the culture medium of fibroblasts from a patient with ALG1-CDG and an unaffected control. After 16 h, there was an 86% reduction of N-tetrasaccharide in ALG1-CDG cells, along with increased amounts of high-mannose and sialylated N-glycans (Fig. 3D) . Addition of 100 mol/L mannose did not produce detectable changes in the profiles of N-glycans, and addition of 200 mol/L mannose produced minimal normalization (data not shown). Given these results, we measured plasma N-glycan from a patient with MPI-CDG before and after the patient's diet had been supplemented with mannose for 6 months and observed reduced concentrations of the tetrasaccharide m/z 1124 in plasma (Fig. 3, E and F) . The carbohydratedeficient transferrin concentrations in this patient also improved markedly after the mannose therapy (data not shown). Interestingly, the increase of Man 3 GlcNAc 2 and Man 4 GlcNAc 2 did not appear to improve. It is possible that mannose supplementation rescued GDP-mannose deficiency in the liver and normalized the glycosylation of transferrin in the patient, but may have had less effect on the GDP-mannose deficiency in other tissues.
Discussion
Although the N-tetrasaccharide was a minor glycan species on transferrin of patients with ALG1-CDG and PMM2-CDG (Table 2) , on the basis of these preliminary studies, it is a potential diagnostic biochemical marker. However, we caution that the MALDI-TOF signal has a very narrow dynamic range and should not be used for quantitative interpretation. Quantification by LC-MS/MS should be considered if this tetrasaccharide is used as a biomarker to monitor treatment or disease progression. Small N-glycans have been recently discovered but not well studied. N-linked chitobiose has been observed in primary cancer cells cultured under hypoglycemic conditions as well as in alg1-deficient yeast (8 ) , but to the best of our knowledge, this galactosylated or sialylated form of N-linked chitobiose has not been reported previously. The discovery of these small N-glycans points to a previously unrecognized Golgi-associated secretory pathway for N-linked protein glycosylation (Fig. 4) . It is known that terminal sialylation of N-linked glycans is important for the survival of hosts during bacterial infection (8 ) . The presence of this alternative pathway could be an adaptive way for cells to maintain terminal sialylation under the circumstance of starvation (8 ) .
Intriguingly, the pentasaccharide Man 3 GlcNAc 2 was increased in all 20 patients with PMM2-CDG and 1 patient with MPI-CDG. Specifically, our data show that the combination of increased N-linked tetrasaccharide and Man 3 GlcNAc 2 excludes a diagnosis of ALG1-CDG and instead supports a diagnosis of PMM2-CDG or MPI-CDG. This arises because the deficiency of GDPmannose in PMM2-CDG or MPI-CDG potentially affects every step of mannosylation in the endoplasmic reticulum (Fig. 4) (Figs. 1C and 3E) . The possible alternative pathways in PMM2-CDG and MPI-CDG are described in Fig. 4 .
Our data show that increased concentrations of the N-tetrasaccharide, together with a concentration of Man 3 GlcNAc 2 that is within the reference range or low, could be potentially diagnostic for ALG1-CDG, because in ALG1-CDG only the ␤1,4-mannosyltransferase is deficient and there is no increase of other downstream intermediates from downstream mannosylation steps in the endoplasmic reticulum.
The ability to detect the N-tetrasaccharide and Man 3 GlcNAc 2 by LC-MS/MS or MALDI-TOF-MS provides a reliable biochemical diagnostic screen for ALG1-CDG and PMM2-CDG or MPI-CDG that is important because it facilitates diagnosis of the 3 most common type I CDGs (9 ) . N-glycan profiling by MALDI-TOF analysis is available as a routine clinical test and is often used as one of the first-tier screening tests in combination with transferrin analysis. Although whole-exome and whole-genome sequencing greatly facilitate diagnoses of rare genetic disorders, establishing a diagnosis for patients with CDG remains challenging because the majority of patients with CDG carry rare missense mutations of undefined functional significance (10 ) . The fact that there are 14 pseudo genes of ALG1 makes molecular analysis of ALG1-CDG more difficult. The discovery of biochemical biomarkers should therefore greatly improve the efficiency of diagnosing these CDGs. Although transferrin glycoforms with this tetrasaccharide could be detected in some patients with ALG1-CDG by routine transferrin analysis with ESI-MS, the concentrations detected are very low and are undetectable in PMM2-CDG or MPI-CDG. Other transferrin test methods such as isoelectric focusing or HPLC are less analytically sensitive than ESI-MS and likely will not detect these glycoforms. Therefore, the combination of routine transferrin and N-glycan analysis by mass spectrometric analysis of plasma or serum is a better first-tier screening strategy for N-glycosylation disorders than transferrin analysis alone.
So far, carbohydrate-deficient transferrin has been the predominant biomarker for the diagnosis and treat- Patients with PMM2 and MPI have deficiencies indicated by the red X in the biosynthesis of GDP-Man. N-glycosylation of a glycoprotein is initiated in the lumen of the rough endoplasmic reticulum by transfer of a glycan precursor from its dolichol-linked precursor to Asn residues (-Asn-X-Ser/Thr) in a nascent polypeptide through ribosomal-directed synthesis. Three possibilities for abnormal glycosylation are shown in the upper panel, involving transfer of 2 N-acetylglucosamine (GlcNAc) residues, transfer of Mannose 3 GlcNAc 2 (Man 3 GlcNAc 2 ), and transfer of Man 4 GlcNAc 2 . After N-glycosylation in the endoplasmic reticulum, glycoproteins move to the Golgi apparatus, where they are subject to further modification by addition of galactose (Gal) and sialic acid (Neu5Ac) by appropriate glycosyltransferases. After completion of glycosylation, the glycoproteins may move to the plasma membrane and be secreted. Orange arrows indicate upregulation in the production of these unusually glycosylated forms in the plasma, serum, and fibroblasts of patients with PMM2-CDG or MPI-CDG. ment monitoring of patients with CDG. The majority of cells, however, do not express transferrin, and this has hindered the use of cellular models to develop treatments for CDG. Although alternative cellular expression systems have been developed (11 ), they have been technically difficult to implement and maintain. Our observation that the N-tetrasaccharide is easily measurable in fibroblast lysates from patients with ALG1-CDG or PMM2-CDG therefore highlights the potential for identifying biomarkers usable in cellular models. Consistent with the diagnostic value of this biomarker, cell lines carrying certain ALG1-CDG mutations demonstrate a response to mannose supplementation. The applicability of mannose treatment for patients with ALG1-CDG remains unknown because not all the ALG1-CDG mutant cell lines respond to mannose supplementation. For instance, cells homozygous for S258L do not respond to mannose supplementation (data not shown), and the concentration of mannose used in vitro may be greater than the concentration that can be achieved in vivo (12 ) .
Because different glycoproteins carry different types of complex N-glycans, monitoring changes of different N-glycan biomarkers could also help us understand the delivery of mannose therapy to different organs in patients with CDG. Our finding that only N-tetrasaccharide was reduced after mannose therapy without reduction in Man3GlcNAc2 or Man4GlcNAc2 indicates the potential limitation of oral mannose therapy in patients with CDG, and that future studies are warranted to investigate the effects of mannose therapy on glycoproteins in different human tissues.
In summary, we have identified a novel sialylated N-tetrasaccharide that completely lacks mannose and have shown that it is a useful biomarker for the detection of deficient mannosylation in N-glycosylation by MALDI-TOF-MS or LC-MS/MS analysis. The discovery of this N-tetrasaccharide also implies an alternative Golgi apparatus-associated secretory pathway of protein N-glycosylation. Because of our limited understanding of genetic defects that lead to GDP-mannose deficiency, our study included only 3 known CDG subtypes, ALG1-CDG, PMM2-CDG, and MPI-CDG. As new CDG subtypes are being discovered, a similar mannose deficient N-glycan profile may be seen in other new defects in the same or adjacent pathways.
